Objective: To explore the clinical efficacy of Zhibitai capsules combined with atorvastatin calcium in the treatment of coronary heart disease. Method: 89 patients with coronary heart disease admitted to Dehui Traditional Chinese Medicine Hospital from March 2017 to March 2019 were selected as the research subjects. They were randomly divided into an observation group of 45 cases and a control group of 44 cases using a random number table method. Both groups of patients were treated with routine symptomatic therapies such as nitrates, calcium antagonists, and angiotensin converting enzyme inhibitors. The control group was treated with atorvastatin calcium tablets on this basis, while the observation group was treated with Zhibitai capsules combined with atorvastatin calcium tablets. Compare the clinical efficacy of two groups of patients and observe the changes in blood lipid indicators before and after treatment. The total effective rate of the observation group was 91.1% (41/45), which was higher than 75.0% (33/44) of the control group, and the difference between the two groups was statistically significant( χ 2=6.937, P<0.05). After treatment, the total cholesterol (TC) in the observation group was (1.69 ± 0.31) mmol/L and triglycerides (TG) was (3.54 ± 0.41) mmol/L, respectively. The control group was (2.04 ± 0.35) mmol/L and (4.11 ± 0.49) mmol/L, respectively. Both groups were lower than before treatment (control group: t=6.671, 5.681, observation group: t=12.495, 10.456, all P<0.05), and the observation group was lower than the control group, with statistically significant differences (t=6.357, 6.120, all P<0.05). Conclusion: On the basis of routine treatment, the combination of Zhibitai capsules and atorvastatin calcium tablets can improve clinical efficacy and effectively regulate blood lipid levels in the treatment of coronary heart disease.
期刊介绍:
Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.